Company news

UroGen Pharma Ltd. news in 2023

UroGen Pharma Ltd.'s news releases, calls and decks from 2023, newest first.

View company

UroGen Pharma Reports Third Quarter 2023 Financial Results

November 13, 2023

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

November 12, 2023

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

November 6, 2023

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

October 2, 2023

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

August 9, 2023

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 7, 2023

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 1, 2023

UroGen Announces $120 Million Private Placement of Ordinary Shares

July 26, 2023

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

July 26, 2023

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

July 24, 2023

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

July 9, 2023

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

July 5, 2023

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

June 19, 2023

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 8, 2023

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 10, 2023

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

May 3, 2023

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

April 30, 2023

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

April 29, 2023

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

April 24, 2023

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

March 15, 2023

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

March 8, 2023

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

February 14, 2023

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 10, 2023

Calls in 2023

Decks in 2023